|
US2018043017A1
|
|
Pharmaceutical compositions comprising 0.5 mg dose of synthetic human peptides for treating systemic lupus erythematosus
|
|
US2018043016A1
|
|
Pharmaceutical compositions comprising 0.25 mg dose of synthetic human peptides for treating systemic lupus erythematosus
|
|
AP200904840A0
|
|
Compounds and methods for treatment of HCV
|
|
CN101668528A
|
|
Compounds and methods for treatment of hcv
|
|
EP2061466A2
|
|
4-thio substituted quinoline and naphthyridine compounds
|
|
US2006258682A1
|
|
Benzofuran compounds
|
|
KR20070122554A
|
|
Stabilized anti-hepatitis b (hbv) antibody formulations
|
|
US2006223783A1
|
|
3,4-disubstituted coumarin and quinolone compounds
|
|
US2005260195A1
|
|
Treatment of hepatitis B virus infection with human monoclonal antibodies
|
|
US7148253B2
|
|
4-thio coumarins
|
|
AU2003238650A1
|
|
A method for discovery of human genes associated with viral hepatitis infection
|
|
WO03028722A1
|
|
Treatment of hepatitis b virus infection with human monoclonal antibodies
|
|
IL145440D0
|
|
Synthetic hcv envelope proteins and their use for vaccination
|
|
IL150618D0
|
|
A method for discovery of human genes associated with viral hepatitis infection
|
|
USRE39586E
|
|
Human monoclonal antibody against Hepatitis B virus surface antigen (HBVSAG)
|
